Multiple Dates

SDIC Webinar Series- Drug Repurposing

Actions and Detail Panel


Event Information

Share this event

Date and time



Online event

Event description
Emerging Topics in Drug Repositioning and Drug Repurposing

About this event

Eyal Barash of Barash Law LLC, will be presenting on the following topic.

Drug repurposing is traditionally defined as the use of a known drug for an indication other than the one for which approval was initially sought. Serendipitous discovery has historically been a key part of drug repurposing. For example, when the compound sildenafil was first synthesized in the 1980s, Pfizer was looking for a treatment for angina. The drug lacked the desired antihypertensive effects. However, the researchers later learned—from initial volunteer reports and then confirmed with large-scale studies—that sildenafil could be used to treat erectile dysfunction. Thus, Viagra® was born from the repurposing of sildenafil. Similarly, thalidomide was first marketed in 1957 to pregnant women as a sedative and treatment for morning sickness. After it was discovered that the intended use caused skeletal birth defects in thousands of the children whose mothers had taken the drug, thalidomide was removed from circulation in Europe and never marketed in the United States. Today, however, it is used to treat multiple myeloma.

This talk will discuss an emerging intellectual property aspect of drug repurposing – not the mechanism by which novel methods of treatment or even formulations are patented, but how modifying properties such as drug delivery can create brand new classes of intellectual property. We will discuss how such intellectual property can add tremendous value to a pharmaceutical asset and how resulting patents are prosecuted and litigated. As drug development timelines lengthen and with the advent of machine-learning methods to tease out clinical signals from older compounds, the time is ripe to consider new methods for obtaining intellectual property on older assets.

This seminar is divided into two parts. In part I, on October 14th at 11:30am Pacific, we will introduce these new trends in drug repurposing. In part II, on October 28th at 11:30am Pacific, we will go into more detail on how to take advantage of these trends.

Eyal founded Barash Law LLC in 2009 to be a “roving” in-house General and IP counsel to early and mid-stage start-ups primarily coming out of the Purdue Research Park in West Lafayette, Indiana. He advises or has advised more than 20 start-up companies from Purdue alone and taken them through multiple stages of development including in-licenses, out-licenses, public offerings, private sales and public exits. In 2018, one of Eyal’s clients, Endocyte, Inc. was sold to Novartis for over $2B. Eyal was chief patent counsel to Endocyte for almost 10 years. Eyal is also a prolific speaker and lecturer, giving presentations primarily in life science IP throughout the globe. He has a particular interest in drug repositioning and repurposing and lectures on this topic frequently. Eyal’s current clients have a global footprint and are in the pharmaceutical, medical device, energy, defense, and agriculture sectors.

Share with friends


Online event

Organizer Barash Law LLC

Organizer of SDIC Webinar Series- Drug Repurposing

Save This Event

Event Saved